CVnCoV – CureVac AG vs placebo
Systemic reactogenicity events
CVnCoV – CureVac AG leads to higher systemic reactogenicity eventsi compared with placebo (high certainty).
1 finding from 1 review
- RR 1.48 [1.43, 1.53]1 study · 3982 participantsHigh
CVnCoV – CureVac AG leads to higher systemic reactogenicity eventsi compared with placebo (high certainty).